Other
Jun 2025Co-founder Richard Barrett publicly said Guardian Bio was being put into hibernation; Ananya Zutshi posted the same day confirming hibernation and that both founders were moving on to new opportunities.
SourceDendritic cell-based platform for cancer therapy
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Guardian Bio is a Boston-based biotechnology startup founded in 2022 that developed a patient-derived cDC1 dendritic-cell therapy platform (Guard-cDC1) for late-stage solid tumors, combining regenerative medicine with immunotherapy. Public evidence suggests the company later entered hibernation in June 2025 after a small preclinical program backed by Y Combinator and other early-stage support.
Primary product
Guard-cDC1, a patient-derived cDC1 dendritic-cell therapy platform for late-stage solid tumors
Founded
2022
Headquarters
Boston, Massachusetts, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Immunotherapy / cell therapy
Business model
biotechnology R&D
cell therapy development
oncology therapeutics
Funding
Stage
seed
Total raised
$500K
Latest round
Incubator/Accelerator · Jul 2023
Jan 2024
Jul 2023 · Creative Destruction Lab
Sep 2022
Jan 2022 · Y Combinator
People & investors
Leadership
Co-Founder and CEO
Karolina Palucka
Academic Co-Founder, Chair, Scientific Advisory Board
Founders
Co-Founder
Work & culture
Mission-driven, translational biotech focused on bringing scientific advances to patients; public founder commentary emphasizes patient impact, scientific ambition, and diversity, equity, and inclusion. No public benefits package details were found.
Product & market
Differentiators
- —Generates true cDC1-like cells from a patient’s own stem cells
- —Targets the dendritic-cell antigen-presentation bottleneck in cancer
- —Aims to elicit multi-target anti-tumor immune responses
- —Combines regenerative medicine with immunotherapy
Technology
dendritic cell engineering
cDC1 differentiation
patient stem cell processing
cell therapy manufacturing
immuno-oncology
regenerative medicine
Customers
late-stage solid tumor cancer patients
oncology clinicians and clinical collaborators
Competitors
Sana Biotechnology
BeiGene
Jazz Pharmaceuticals
Signals & risks
Latest news
Medium · Jun 2025
A post-mortem-style reflection from Richard Barrett describing Guardian Bio’s fundraising journey, grant/pitch support, the move toward clinical proof-of-concept, and the eventual decision to stop due to lack of capital and runway.
LinkedIn · Jun 2025
Richard Barrett said Guardian Bio was being put into hibernation and that the founders were moving on to new opportunities; he also noted the team had built a novel cell-therapy platform and would publish a reflection on the journey.
LinkedIn · Jun 2025
Ananya Zutshi confirmed Guardian Bio was entering hibernation and said the company would remain in hibernation while they shared a reflection on the experience.
LinkedIn · Jul 2024
Y Combinator said Guardian Bio (YC S22) was focused on engineering dendritic cells to target solid tumors and moving rapidly toward the clinic based on promising preclinical results.
LinkedIn · Jan 2024
Guardian Bio announced it was one of five Massachusetts companies awarded the MassNextGen grant, saying the funding would support efforts to bring its first-in-class dendritic-cell therapy to the clinic.
Jobs and careers at Guardian Bio
0 jobs at Guardian Bio
No open positions
Check back later for new openings